Hyloris Pharmaceuticals SA
EBR:HYL.BR
4.8 (EUR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 2.087 | 2.951 | 3.096 | 0.175 | 0.091 | 0.091 | 0.213 |
| Cost of Revenue
| 0.441 | 0.094 | 0.107 | 0.145 | 0.066 | 0.065 | 0.095 |
| Gross Profit
| 1.646 | 2.857 | 2.989 | 0.03 | 0.025 | 0.026 | 0.118 |
| Gross Profit Ratio
| 0.789 | 0.968 | 0.965 | 0.171 | 0.275 | 0.286 | 0.554 |
| Reseach & Development Expenses
| 14.421 | 10.151 | 5.056 | 3.413 | 4.577 | 4.87 | 2.313 |
| General & Administrative Expenses
| 5.546 | 3.517 | 2.9 | 2.194 | 0.808 | 0.622 | 1.657 |
| Selling & Marketing Expenses
| -0.348 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.198 | 3.517 | 2.9 | 2.194 | 0.808 | 0.622 | 1.657 |
| Other Expenses
| -2.127 | -0.303 | 5.381 | -1.468 | -0.086 | 0.003 | 0.013 |
| Operating Expenses
| 19.619 | 13.365 | 13.337 | 5.607 | 5.299 | 5.495 | 3.983 |
| Operating Income
| -17.973 | -10.508 | -10.348 | -5.577 | -5.274 | -5.469 | -3.866 |
| Operating Income Ratio
| -8.612 | -3.561 | -3.342 | -31.869 | -57.956 | -60.099 | -18.15 |
| Total Other Income Expenses Net
| 2.147 | -0.258 | -0.934 | -1.568 | -0.508 | -0.59 | 0.082 |
| Income Before Tax
| -15.826 | -10.766 | -11.282 | -7.145 | -5.782 | -6.059 | -3.783 |
| Income Before Tax Ratio
| -7.583 | -3.648 | -3.644 | -40.829 | -63.538 | -66.582 | -17.761 |
| Income Tax Expense
| -0.593 | 0.004 | 0.297 | 0.001 | -0.014 | -0.02 | -0.066 |
| Net Income
| -15.38 | -10.77 | -11.579 | -7.146 | -5.768 | -5.791 | -3.717 |
| Net Income Ratio
| -7.369 | -3.65 | -3.74 | -40.834 | -63.385 | -63.637 | -17.451 |
| EPS
| -0.55 | -0.4 | -0.45 | -0.28 | -1.15 | -0.25 | -0.16 |
| EPS Diluted
| -0.55 | -0.4 | -0.45 | -0.28 | -1.15 | -0.25 | -0.16 |
| EBITDA
| -17.625 | -10.225 | -10.589 | -5.674 | -2.065 | -5.631 | -3.572 |
| EBITDA Ratio
| -8.445 | -3.465 | -3.42 | -32.423 | -22.692 | -61.879 | -16.77 |